A Phase I Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral and Subcutaneous Injection in Patients With Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-type

What is the purpose of this trial?

The primary objective of this study is to evaluate the safety and tolerability of the investigational drug, MRG-106, in patients with cutaneous T-cell lymphoma (CTCL), mycosis fungoides subtype. MRG-106 is an inhibitor of a molecule called miR-155 that is found at high levels in the malignant T-cells of many mycosis fungoides patients. miR-155 may be important in promoting the growth and survival of these cancer cells. In Part A of the study, MRG-106 will be tested by injection directly into CTCL lesions in the skin. In Part B of the study, MRG-106 will be given by subcutaneous injection. Other objectives of the study are to measure the absorption and clearance of MRG-106 from the blood, and to understand how cells in CTCL skin lesions respond when exposed to MRG-106.



miRagen Therapeutics, Inc.

Start Date: 01/25/2016

End Date: 12/01/2018

Last Updated: 04/05/2018

Study HIC#: 1507016232

Get Involved

For more information about this study, contact:
Laura Leary
laura.leary@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Francine Foss

Principal Investigator

Sub-Investigators